Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × durvalumab × Clear all

Phase

Phase 2 14 Phase 1/2 3 Phase 1 3 Phase 4 1 Phase 3 1

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 27 Small Cell Lung Carcinoma 7 Lung Neoplasms 7 Biliary Tract Neoplasms 7 Carcinoma, Hepatocellular 5 Urinary Bladder Neoplasms 4 Carcinoma 4 Liver Neoplasms 3 Recurrence 2 Neoplasm Metastasis 2 Gallbladder Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Renal Cell 2 Urothelial Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma Extensive Disease 1 Sarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancoast Syndrome 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Non Small Cell Lung Carcinoma NSCLC 1 Non Small Cell Lung Cancer NSCLC 1 Non - Small Cell Lung Cancer NSCLC 1 Neoplasms 1 Mesothelioma, Malignant 1 Mesothelioma 1 Locally Advanced or Metastatic EGFR T790M+ NSCLC 1 Locally Advanced Cervical Cancer 1

Interventions

Paclitaxel 19 Dexamethasone 16 Bevacizumab 16 Oxaliplatin 14 Docetaxel 14 Capecitabine 12 Gemcitabine 11 Cyclophosphamide 11 Sorafenib 10 Leucovorin 10 Fluorouracil 10 Carboplatin 10 Epoetin Alfa 9 pembrolizumab 8 Pemetrexed 8 Fentanyl 8 venetoclax 7 atezolizumab 7 Rivaroxaban 6 Prednisone 6 Ondansetron 6 Morphine 6 Irinotecan 6 Drug Therapy 6 Doxorubicin 6 Denosumab 6 Cisplatin 6 Tranexamic Acid 5 Sodium Chloride 5 Panitumumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05303532 2026-02-23

ROSY-D

AstraZeneca

Phase 3 Enrolling by invitation

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡